Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Mar 30;21(4):423.
doi: 10.3390/ijerph21040423.

Non-Pharmacological Interventions for Type 2 Diabetes in People Living with Severe Mental Illness: Results of a Systematic Review and Meta-Analysis

Omorogieva Ojo  1 , Erika Kalocsányiová  2 , Paul McCrone  2 , Helen Elliott  3 , Wendy Milligan  1 , Evdoxia Gkaintatzi  2
Affiliations
Meta-Analysis

Non-Pharmacological Interventions for Type 2 Diabetes in People Living with Severe Mental Illness: Results of a Systematic Review and Meta-Analysis

Omorogieva Ojo et al. Int J Environ Res Public Health. .

Abstract

Background: People with serious mental illnesses (SMIs) such as schizophrenia and bipolar disorder die up to 30 years younger than individuals in the general population. Premature mortality among this population is often due to medical comorbidities, such as type 2 diabetes (T2D). Being a disease directly related to diet, adverse lifestyle choices, and side effects of psychotropic medication, an effective approach to T2D treatment and management could be non-pharmacological interventions. This systematic review and meta-analysis (1) summarise the current evidence base for non-pharmacological interventions (NPI) for diabetes management in people living with SMI and (2) evaluate the effect of these interventions on diverse health outcomes for people with SMI and comorbid diabetes.

Methods: Six databases were searched to identify relevant studies: PubMed (MEDLINE), PsycINFO, Embase, Scopus, CINAHL, and Web of Science. Studies were included if they reported on non-pharmacological interventions targeted at the management of T2D in people living with SMI. To be eligible, studies had to further involve a control group or report multiple time points of data in the same study population. Whenever there were enough interventions reporting data on the same outcome, we also performed a meta-analysis.

Results: Of 1867 records identified, 14 studies were included in the systematic review and 6 were also eligible for meta-analysis. The results showed that there was a reduction, although not significant, in glycated haemoglobin (HbA1c) in the NPI group compared with the control, with a mean difference of -0.14 (95% CI, -0.42, 0.14, p = 0.33). Furthermore, NPI did not significantly reduce fasting blood glucose in these participants, with a mean difference of -17.70 (95% CI, -53.77, 18.37, p = 0.34). However, the meta-analysis showed a significant reduction in psychiatric symptoms: BPRS score, -3.66 (95% CI, -6.8, -0.47, p = 0.02) and MADRS score, -2.63 (95% CI, -5.24, -0.02, p = 0.05). NPI also showed a significant reduction in the level of total cholesterol compared with the control, with a mean difference of -26.10 (95% CI, -46.54, -5.66, p = 0.01), and in low-density lipoprotein (LDL) cholesterol compared with control, with a standardised mean difference of -0.47 (95% CI, -0.90, -0.04, p = 0.03). NPI did not appear to have significant effect (p > 0.05) on body mass index (BMI), health-related quality of life (HRQL), triglycerides, and high-density lipoprotein cholesterol compared with control.

Conclusions: This systematic review and meta-analysis demonstrated that NPI significantly (p < 0.05) reduced psychiatric symptoms, levels of total cholesterol, and LDL cholesterol in people with type 2 diabetes and SMI. While non-pharmacological interventions also reduced HbA1c, triglyceride, and BMI levels and improved quality of life in these people, the effects were not significant (p > 0.05).

Keywords: blood glucose parameters; body mass index; co-morbidity; lipid profile; non-pharmacological interventions; psychiatric symptoms; severe mental illness; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
PRISMA flow diagram.
Figure 2
Figure 2
(a) The effect of non-pharmacological intervention on glycated haemoglobin (%) [19,22,23,24,28]. (b) The effect of non-pharmacological intervention on fasting blood glucose (log transformation) [23].
Figure 3
Figure 3
(a) The effect of non-pharmacological intervention on BPRS (score) [18,19]. (b) The effect of non-pharmacological intervention on MADRS (score) [28]. (c) The effect of non-pharmacological intervention on PHQ-9 (score) [19].
Figure 4
Figure 4
The effect of non-pharmacological intervention on Short Form Health Survey-36 (SF-36) (score) [28].
Figure 5
Figure 5
(a) The effect of non-pharmacological intervention on total cholesterol [23]. (b) The effect of non-pharmacological intervention on LDL cholesterol [19,23].
Figure 6
Figure 6
The effect of non-pharmacological intervention on body mass index [19,23,24].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sun H., Saeedi P., Karuranga S., Pinkepank M., Ogurtsova K., Duncan B.B., Stein C., Basit A., Chan J.C., Mbanya J.C., et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 2022;183:109119. doi: 10.1016/j.diabres.2021.109119. - DOI - PMC - PubMed
    1. Ong K.L., Stafford L.K., McLaughlin S.A., Boyko E.J., Vollset S.E., Smith A.E., Dalton B.E., Duprey J., Cruz J.A., Hagins H., et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402:203–234. doi: 10.1016/S0140-6736(23)01301-6. - DOI - PMC - PubMed
    1. Nanda M., Sharma R., Mubarik S., Aashima A., Zhang K. Type-2 Diabetes Mellitus (T2DM): Spatial-temporal Patterns of Incidence, Mortality and Attributable Risk Factors from 1990 to 2019 among 21 World Regions. Endocrine. 2022;77:444–454. doi: 10.1007/s12020-022-03125-5. - DOI - PubMed
    1. Safiri S., Karamzad N., Kaufman J.S., Bell A.W., Nejadghaderi S.A., Sullman M.J.M., Moradi-Lakeh M., Collins G., Kolahi A.-A. Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results from the Global Burden of Disease Study 2019. Front. Endocrinol. 2022;13:838027. doi: 10.3389/fendo.2022.838027. - DOI - PMC - PubMed
    1. Mazereel V., Detraux J., Vancampfort D., van Winkel R., De Hert M. Impact of Psychotropic Medication Effects on Obesity and the Metabolic Syndrome in People with Serious Mental Illness. Front. Endocrinol. 2020;11:573479. doi: 10.3389/fendo.2020.573479. - DOI - PMC - PubMed

Publication types

MeSH terms